A study at The Wistar Institute revealed that Satb1 expression is required for proper immune response, but its prolonged presence drives immunosuppressive behavior. Silencing Satb1 in tumor-associated dendritic cells boosted T-cell activation and reduced inflammation.
Researchers developed statistical methods to analyze HIV-infected infant data, showing early ART treatment preserves immune system function. The study suggests better treatment strategies can be initiated shortly after birth.
Scientists at The Wistar Institute discovered that p53 can suppress accumulated DNA damage at telomeres, preserving genome integrity. This finding highlights a new benefit of the vital gene p53 in protecting against cancer.
Researchers at The Wistar Institute used patient-derived xenograft (PDX) mouse models to test a combination of targeted therapies against relapsed melanoma. A MET inhibitor called capmatinib, when combined with BRAF and MEK inhibitors, showed significant tumor regression in all animals, suggesting a possible new mechanism of resistance.
Studies reveal that long-term sex work may increase HIV-1 resistance through changes in the cervical and vaginal microenvironment. Women who remain uninfected despite repeated sexual activity exhibit lower immune activation, enhanced expression of interferon ε, and reduced expression of genes critical for HIV survival.
Scientists at The Wistar Institute have discovered how the SPOP gene suppresses tumor growth through induced senescence. When the gene is functioning properly, it acts as a tumor suppressor and induces senescence in cells.
Scientists at The Wistar Institute have developed a highly specific telomerase inhibitor that targets the enzyme in approximately 90% of cancers. By binding to a specific pocket on the outer surface of telomerase, the inhibitor prevents the enzyme from properly assembling, leading to cell cycle arrest and senescence.
Researchers have identified an interaction between proteins that helps organize chromosomes to protect vital genetic information during mitosis. This discovery provides a molecular basis for understanding chromosome segregation and its role in diseases characterized by chromosome instability.
Researchers found that PI3K inhibitors reprogram the mitochondria of tumor cells, causing them to produce energy in a localized manner, leading to a more aggressive and invasive phenotype. This paradoxical response may offer a new therapeutic angle for treating cancers.
Researchers at The Wistar Institute identified specific mutations in H3N2 viruses that made the 2014-2015 flu vaccine less effective. Antigenic drift, a phenomenon where viruses accumulate mutations to evade immune response, was found to be a key factor.
Researchers at The Wistar Institute have identified a protein biomarker AKAP4 that appears to be more accurate in detecting non-small cell lung cancer. This discovery could lead to the development of a simple blood test for annual screening, potentially saving lives by detecting the disease earlier.
Researchers at The Wistar Institute have discovered how a specific variant of the condensin protein complex plays a crucial role in regulating DNA structure and promoting cellular senescence. This finding provides valuable insights into the anti-cancer activity of cells and could lead to the development of new therapies
The Wistar Institute has secured a $5.6 million grant renewal from the Wellcome Trust to further develop cancer drugs targeting Epstein-Barr virus (EBV). The goal is to create a therapeutic that can treat EBV-related cancers by attacking the virus as it remains dormant in patient cells.
Scientists at The Wistar Institute have identified a way that cells can reprogram their metabolism to overcome senescence, a tumor-suppressing mechanism. This reprogramming allows for the proliferation of cells that should have become senescent and has the potential to lead to tumor formation.
Researchers discovered that macrophages activate the MAPK pathway, leading to increased tumor growth. Blocking this pathway reverses macrophage-mediated resistance and increases antitumor activity of BRAF inhibitors.
The Wistar Institute has received a $1.1 million grant from the Jayne Koskinas Ted Giovanis Foundation to support the work of three scientists researching metastatic breast cancer. The researchers aim to develop novel targeted therapies by understanding the pathways essential to breast cancer cells.
Researchers at The Wistar Institute have identified a new therapeutic target in ovarian clear cell carcinoma, a difficult-to-treat subtype of ovarian cancer. EZH2 inhibition causes regression of ovarian tumors with ARID1A mutation, providing a much-needed therapeutic strategy for clear cell ovarian cancer.
Chronic inflammatory conditions are directly associated with several types of cancer, but the cellular mechanisms behind this link were unclear. An international team of scientists has identified a multistep process showing how these cancers develop, providing potential therapeutic targets for halting tumor cell formation.
A study by The Wistar Institute found that a polymorphism in the TLR5 gene affects tumor progression and inflammation in breast and ovarian cancers. In individuals with functional TLR5 expression, commensal bacteria stimulate IL-6 production, leading to suppressed antitumor immune activity.
Researchers found that herpes simplex virus 1 rearranges telomeres to improve viral replication, suggesting a molecular mechanism for viral efficiency. The study also highlights the role of telomere proteins in protecting against viral infection.
Researchers at The Wistar Institute identified a new viral mutation that may explain why middle-aged adults were disproportionately affected by the H1N1 virus in 2013-2014. The study suggests that updating seasonal influenza vaccines with new viral strains could be crucial to protect this population.
The Wistar Institute and Penn Medicine have collaborated on a $12.1 million SPORE grant to develop new therapies for melanoma. The goal of this project is to translate fundamental laboratory discoveries into new therapeutics that will benefit patients with melanoma and other skin cancers.
Researchers at The Wistar Institute discovered that mice lacking TRAP-1 protein live longer lives with fewer age-related illnesses. TRAP-1 is an important regulator of metabolism and has been shown to regulate energy production in mitochondria, organelles that generate chemically useful energy for the cell.
Researchers found that prior colonization by Streptococcus pneumoniae protected mice from severe disease and pneumonia. The protective effect was linked to the bacterial virulence factor pneumolysin, which reduced inflammation in the lungs.
Researchers at The Wistar Institute discovered that the protein Foxp1 plays a critical role in antibody responses, enabling rapid and effective immune system activation. Manipulating Foxp1 activity could provide a useful tool for boosting antibody responses to treat infectious diseases or suppressing them to treat autoimmune disorders.
A study published at The Wistar Institute Cancer Center found that bacterial virulence proteins can suppress DNA repair proteins in epithelial cells, leading to genetic mutations that favor tumor development. This research opens the possibility of modifying colon cancer risk by altering gut bacteria populations.
Researchers at The Wistar Institute have discovered LIMD2, a protein that drives metastasis in various cancers. The study defines the structure of LIMD2 and its correlation with metastatic tumors, offering potential targets for treatment.
The National Cancer Institute (NCI) has rated The Wistar Institute Cancer Center as 'exceptional' and recommended a $14.9 million support grant renewal over five years. This rating highlights the center's commitment to scientific collaboration, research excellence, and translating discoveries into better cancer treatments.
Researchers at The Wistar Institute have developed a mathematical method for classifying glioblastoma tumor cells based on gene transcript variants. This system can predict the subclasses of glioblastoma tumors with 92 percent accuracy, enabling personalized therapies.
A team led by The Wistar Institute will conduct a 4-year, randomized clinical trial to test an immunotherapy strategy that has shown promise in reducing the amount of persistent HIV-1 virus residing in cells. The trial aims to establish the effectiveness of this approach in advancing an HIV cure.
A team of researchers from The Wistar Institute and the University of Pennsylvania are working on a five-year project to better understand melanoma biology and develop more effective treatments for the disease. They aim to overcome drug resistance by targeting different mutations and combinations of therapies.
The study identified Wnt5A as a key player in promoting melanoma metastasis and therapy resistance. By understanding the role of Wnt5A, researchers may be able to identify patients who are more likely to respond to BRAF inhibitors and develop new targeted therapies.
Researchers discovered a potential target for melanoma therapy in the S6K protein and found that a triple combination of drug inhibitors halted the growth of resistant tumors. Early studies also showed no evident signs of toxicity, making this approach a promising new strategy to combat drug-resistant melanoma.
Researchers at The Wistar Institute have discovered a protein motif, TFLY, crucial to telomerase function, which can be disrupted to block enzyme activity. This finding offers new insights into developing drugs to inhibit telomerase and its potential role in cancer therapy.
The Wistar Institute has received a $1.5 million grant from the US Department of Defense to prepare its potential new prostate cancer drug Gamitrinib for trial in humans. The three-year grant will cover the costs of developing the data necessary to allow Gamitrinib's use in the clinic.
The researchers determined the structure of NatA, a protein complex modifying nearly 85% of human proteins, and found it essential for cancer cell proliferation. The team believes their findings will allow them to create an inhibitor that can knock out NatA, potentially curbing cancer growth.
Researchers at The Wistar Institute found that sequential vaccination with distinct influenza strains can stimulate immune responses against multiple strains. This approach offers an alternative to creating a universal flu vaccine by targeting conserved regions of the virus, potentially providing long-term immunity.
Researchers at The Wistar Institute have discovered a way to overcome drug resistance in melanoma by combining anticancer therapies with diabetes drugs. By sensitizing resistant cells, the combined therapy can destroy a subset of drug-resistant cells within a tumor.
Researchers at The Wistar Institute discovered ADAR1's critical role in regulating microRNA synthesis, which is essential for life. The protein combines with Dicer to create miRNA and siRNA, playing a crucial role in silencing specific genes.
Researchers discovered that oncogene-induced senescence can suppress cancer development by depriving cells of nucleotides, the building blocks of DNA. By targeting the RRM2 enzyme, which produces these nucleotides, scientists may be able to stabilize senescence and improve the effectiveness of chemotherapy or targeted drugs.
Researchers at The Wistar Institute discovered a mechanism by which long non-coding RNA-activators promote gene expression in early embryonic development. These RNA molecules help create a loop of DNA, opening up genes for transcription.
Researchers defined the structure of Cdc13, a key telomere maintenance protein in yeast, revealing how its mutations can disrupt telomere function and potentially lead to cancer. The study's findings may pave the way for novel anticancer therapies by targeting the OB2 region of Cdc13.
Researchers created the most comprehensive study of Epstein-Barr virus genome interactions with its human host. The EBV atlas describes over 60 human transcription factors and highlights the extensive coevolution of the virus, pointing toward possible targets for future cancer and anti-viral drugs.
Researchers at The Wistar Institute found that a diverse array of regulatory T cells is necessary to prevent the immune system from generating tissue-specific inflammation in rheumatoid arthritis. This diversity provides a cumulative protective effect against the disease.
Researchers discover small molecule inhibitors that protect a tumor-suppressing protein targeted by viral proteins, killing infected cells. The inhibitors work by binding to the protein itself, allowing it to trigger normal cell division without disrupting the effect of HPV.
Researchers introduce a new 'prediction-based classification' system to reduce the burden of monitoring patients on ART, potentially saving 54% of CD4 tests. The algorithm can prioritize patients who may need routine CD4 count tests, increasing capacity and resources for life-saving treatment.
A clinical trial shows that interferon-alpha can control HIV replication in patients who stop antiretroviral therapy, reducing integrated HIV DNA levels and decreasing reservoirs. The study provides hope for a functional cure and opens the way to further research on HIV eradication.
A new model of aggressive ovarian cancer reveals that dendritic cells actively support tumor progression, but can be restored to suppress it. Researchers propose targeting dendritic cells to control metastatic ovarian cancer.
The Wistar Institute is developing a new drug to treat Epstein-Barr virus-related cancers by targeting the dormant EBV virus in patient cells. The project aims to create a viable drug candidate with potential to save countless lives globally.
Researchers at The Wistar Institute have discovered protein signals responsible for preserving anti-viral antibody memory. The study highlights how BLyS and APRIL sustain cells that produce antibodies against viruses, crucial knowledge for vaccine development.